Ariel Grajales-Cruz, MD

home / authors / ariel-grajales-cruz-md

Articles

Ariel Grajales-Cruz, MD, assistant member, Department of Malignant Hematology, Multiple Myeloma Section, Moffitt Cancer Center; assistant professor, University of South Florida

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

April 4th 2024

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Ariel F. Grajales-Cruz, MD, Moffitt Cancer Center

Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma

Ariel Grajales-Cruz, MD

March 25th 2024

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Dr Grajales-Cruz on the Safety of Teclistamab in Multiple Myeloma

Ariel Grajales-Cruz, MD

March 13th 2024

Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.

Dr Grajales-Cruz on Benefit With Teclistamab in Select Patients With Relapsed/Refractory Myeloma

Ariel Grajales-Cruz, MD

February 27th 2024

Ariel Grajales-Cruz, MD, discusses factors associated with benefit from teclistamab in heavily pretreated relapsed/refractory multiple myeloma.

Dr Grajales-Cruz on Real-World Responses With Teclistamab in Pretreated R/R Multiple Myeloma

Ariel Grajales-Cruz, MD

January 11th 2024

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.